Key result
High-dose amoxicillin/clavulanate was associated with a higher rate of INR ≥ 4 compared to normal doses (87.5% vs 28.9%, P≤0.001), and polypharmacy increased the risk of bleeding (OR 3.1).
Why the study?
Does high-dose amoxicillin/clavulanate and polypharmacy increase the risk of over-anticoagulation and bleeding in hospitalized patients on warfarin?
Cross-Sectional (n=120)
Does high-dose amoxicillin/clavulanate and polypharmacy increase the risk of over-anticoagulation and bleeding in hospitalized patients on warfarin?
Absolute Event Rate: 87.5% vs 28.9%
p-value: p=≤ .001
High-dose amoxicillin/clavulanate and polypharmacy significantly increase the risk of over-anticoagulation and bleeding in hospitalized patients taking warfarin, highlighting the need for frequent monitoring.
The objective of this study was to investigate the effect of polypharmacy and high doses of amoxicillin/clavulanate on warfarin response in hospitalized patients. This was a prospective cross-sectional observational study on 120 patients from July 2013 to January 2014. Potentially interacting drugs were classified according to their tendency of increasing international normalized ratio (INR) or bleeding risk. The 87.5% of patients prescribed high-dose amoxicillin/clavulanate (10-12 g daily) compared with 28.9% of patients prescribed a normal dose (up to 3.6 g daily) had INR values ≥ 4 during the hospital stay (P ≤ .001). Increased number of potentially interacting drugs that are known to increase INR was a significant predictor of having INR values ≥ 4 (OR, 2.5; 95%CI, 1.3-4.7), and increased number of potentially interacting drugs that are known to increase bleeding risk was a significant predictor of experiencing bleeding episodes (OR, 3.1; 95%CI, 1.3-7.3). High doses of amoxicillin/clavulanate were associated with a higher risk of over-anticoagulation when combined with warfarin than were normal doses. Increased risk of having INR ≥ 4 and bleeding events was associated with increased numbers of potentially interacting drugs prescribed, indicating that polypharmacy is a problem of concern. Frequent monitoring of warfarin therapy along with patients' medications is necessary to avoid complications.
No takes yet. Share an insight, caveat, or question.
Abdel‐Aziz et al. (2015) conducted a cross-sectional in Hospitalized patients on warfarin (n=120). High-dose amoxicillin/clavulanate vs. Normal dose amoxicillin/clavulanate (up to 3.6 g daily) was evaluated on INR values ≥ 4 during the hospital stay (p=≤ .001). High-dose amoxicillin/clavulanate was associated with a higher rate of INR ≥ 4 compared to normal doses (87.5% vs 28.9%, P≤0.001), and polypharmacy increased the risk of bleeding (OR 3.1).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: